Last reviewed · How we verify

Cardiovascular events — Treatment Landscape & Competitive Intelligence

Cardiovascular events (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cardiovascular events, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tryvio APROCITENTAN Idorsia Endothelin Receptor Antagonist [EPC] 2025-01-01
olmesartan medoxomil-hydrochlorothiazide OLMESARTAN Cosette Thiazide Diuretic [EPC] 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Cosette · 1 drug in Cardiovascular events
  2. Idorsia · 1 drug in Cardiovascular events

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cardiovascular events:

Cite this brief

Drug Landscape (2026). Cardiovascular events — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cardiovascular-events. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing